Compare Recursion Pharmaceuticals Inc (RXRX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Williams Companies Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Williams Companies Inc trades at $72.43 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 41.3× Recursion Pharmaceuticals Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Williams Companies Inc for 58 Days on average.
| RXRX | WMB | |
|---|---|---|
Market Cap | $2.14B | $88.48B |
Volume | 30,789,535 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $6.79 | $79.40 |
52-Week Low | $2.84 | $56.51 |
Typical Hold Time | 22 Days | 58 Days |
Enterprise Value | $1.66B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Williams Companies (WMB) trades at $71.46, down 1.28% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company benefits from stable fee-based revenues in the midstream energy sector, positioning it well for AI-driven natural gas demand growth.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus target, offering 22% upside potential. Key opportunities include dividend growth strategy and exposure to rising natural gas demand from data centers. Risks include energy market volatility, high debt levels at 52% debt-to-asset ratio, and execution challenges in capital-intensive projects. The stock's valuation at 28.47 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
